Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma

Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma

Abstract Patients with unresectable glioblastomas have a poor prognosis, with median survival of 6–10 months. We conducted a phase II trial of upfront 5‐day temozolomide (TMZ) and bevacizumab (BV) in patients with newly diagnosed unresectable or multifocal glioblastoma. Patients received up to four...

Full description

Bibliographic Details
Main Authors: Emil Lou, Katherine B. Peters, Ashley L. Sumrall, Annick Desjardins, David A. Reardon, Eric S. Lipp, James E. Herndon II, April Coan, Leighann Bailey, Scott Turner, Henry S. Friedman, James J. Vredenburgh
Format: Article
Language:English
Published: Wiley 2013-04-01
Series:Cancer Medicine
Subjects:
Bevacizumab
glioblastoma
neoadjuvant therapy
temozolomide
unresectable
upfront
Online Access:https://doi.org/10.1002/cam4.58

Internet

https://doi.org/10.1002/cam4.58

Similar Items